Document is current

Article History

Received: 16 April 2025

Accepted: 24 June 2025

First Online: 23 July 2025

Declarations

:

: Ethical approval for the study protocol was granted by the Ethics Committee of the PFH Göttingen (reference number: 251981/4) on December 20, 2023. Prior to participation, informed consent was obtained from all participants.

: Not applicable.

: JF, JO, NP, JK, and YS declare no conflict of interest. CG has received honoraria for consulting and lectures within the past three years from Abbvie, Lilly, Novartis Pharma, Hormosan Pharma, Sanofi-Aventis, Lundbeck, Perfood, Vectura Fertin Pharma, Chordate, Pfizer, Dr. Reddys, Merz, Reckitt-Benckiser and TEVA. His research is supported by a grant from the German Research Foundation (DFG). He does not hold any stocks in pharmaceutical companies.